blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3863615

EP3863615 - METHODS FOR THE TREATMENT OF SOLID TUMOR CANCERS USING ILLUDINS AND BIOMARKERS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  11.07.2024
Database last updated on 25.09.2024
FormerRequest for examination was made
Status updated on  16.07.2021
FormerThe international publication has been made
Status updated on  24.04.2020
Most recent event   Tooltip13.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Lantern Pharma Inc.
1920 McKinney Avenue, 7th Floor
Dallas, TX 75201 / US
[2021/33]
Inventor(s)01 / KULKAMI, Aditya
920 McKinney Avenue
Dallas, TX 75201 / US
02 / VEDARAJU, Yuvanesh
920 McKinney Avenue
Dallas, TX 75201 / US
03 / KATHAD, Umesh
920 McKinney Avenue
Dallas, TX 75201 / US
04 / ASAITHAMBI, Arun
920 McKinney Avenue
Dallas, TX 75201 / US
 [2021/33]
Representative(s)Träger, Denis
Dr. Träger & Strautmann
Patentanwälte Partnerschaft mbB
Stüvestrasse 2
49076 Osnabrück / DE
[N/P]
Former [2021/33]Kuttenkeuler, David
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
Application number, filing date19872565.714.10.2019
[2021/33]
WO2019US56039
Priority number, dateUS201862745382P14.10.2018         Original published format: US 201862745382 P
[2021/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020081414
Date:23.04.2020
Language:EN
[2020/17]
Type: A1 Application with search report 
No.:EP3863615
Date:18.08.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 23.04.2020 takes the place of the publication of the European patent application.
[2021/33]
Search report(s)International search report - published on:US23.04.2020
(Supplementary) European search report - dispatched on:EP30.06.2022
ClassificationIPC:A61K31/122, C07C239/14, C12Q1/686, A61K31/17, A61P35/00, C12Q1/6886
[2022/31]
CPC:
C12Q1/6886 (EP); A61K31/122 (EP); A61K31/17 (EP);
A61P35/00 (EP); C12Q2600/158 (EP)
Former IPC [2021/33]A61K31/122, C07C239/14, C12Q1/686
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/33]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON KREBSEN MIT SOLIDEN TUMOREN UNTER VERWENDUNG VON ILLUDINEN UND BIOMARKERN[2021/33]
English:METHODS FOR THE TREATMENT OF SOLID TUMOR CANCERS USING ILLUDINS AND BIOMARKERS[2021/33]
French:PROCÉDÉS DE TRAITEMENT DE CANCERS À TUMEUR SOLIDE À L'AIDE D'ILLUDINES ET DE BIOMARQUEURS[2021/33]
Entry into regional phase14.05.2021National basic fee paid 
14.05.2021Search fee paid 
14.05.2021Designation fee(s) paid 
14.05.2021Examination fee paid 
Examination procedure14.05.2021Examination requested  [2021/33]
30.01.2023Amendment by applicant (claims and/or description)
10.07.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
21.09.2021Renewal fee patent year 03
23.08.2022Renewal fee patent year 04
22.08.2023Renewal fee patent year 05
13.08.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[IY]WO2007019308  (UNIV CALIFORNIA [US], et al);
 [XY]US9725769  (KNUDSEN STEEN [US]);
 [I]WO2018170230  (MEMORIAL SLOAN KETTERING CANCER CENTER [US]);
International search[Y]US2008306147  (MCMORRIS TREVOR C [US], et al) [Y] 19/19, 19/18 * ; paragraphs [0005], [0031] *;
 [Y]US2016015658  (KELNER MICHAEL [US]) [Y] 1-6, 9-10, 15 * ; abstract; paragraphs [0234]-[0236], [0281] *;
 [XY]US2018100197  (KNUDSEN STEEN [US]) [X] 16-18 * ; paragraphs [0005]-[0007], [0018], [0031], [0073]-[0074], [0123], [0127], pages 35-36 * [Y] 1-7, 9-10, 15, 19/16, 19/18;
 [A]WO2018170230  (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) [A] 1-7, 9-10, 15-18, 19/16, 19/18* ; entire document *;
 [Y]  - PIETSCH, KE et al., "Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities", Chemical Research in Toxicology, (20130118), vol. 26, no. 1, doi:10.1021/tx300430r, pages 146 - 155, XP055415547 [Y] 7 * ; abstract *

DOI:   http://dx.doi.org/10.1021/tx300430r
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.